Immunotherapy-Chemo combo aims to make inoperable esophageal cancer removable
NCT ID NCT06165380
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining the immunotherapy drug cardenilimab with standard chemotherapy can shrink locally advanced esophageal cancer that cannot be surgically removed at first. The goal is to turn these tumors into operable ones, potentially improving survival. About 43 adults with this specific type of esophageal cancer will receive the combination treatment, and researchers will measure how many patients' tumors shrink enough for surgery and whether they achieve a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cardenilimab combined with chemotherapy
- What this could lead to
- If successful, this combination could shrink inoperable esophageal tumors enough to allow surgical removal, potentially improving long-term outcomes.
- What could go wrong
- This is an early-phase trial with only 43 participants, so results may not apply broadly. The treatment may cause side effects from both chemotherapy and immunotherapy, and it might not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
- Smart T-Cell engager aims to outsmart tumors in first human test